Bcl-xL inhibition - a novel strategy for glioma therapy.
Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.|Department of Neurosurgery, Ulm University Medical Center, Ulm, Germany.
Georg
G
Karpel-Massler
Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.
Markus D
MD
Siegelin
D000814:Aniline Compounds / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy; D015398:Signal Transduction / Q000187:drug effects; D013449:Sulfonamides / Q000494:pharmacology*; D051020:bcl-X Protein / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000814:Aniline Compounds; D000970:Antineoplastic Agents; C494811:BCL2L1 protein, human; D013449:Sulfonamides; D051020:bcl-X Protein; C528561:navitoclax
ABT263; L-asparaginase; Usp9X; apoptosis; glioblastoma
Blood. 2013 Nov 14;122(20):3521-32
24014241
Lancet Oncol. 2016 Jun;17(6):768-778
27178240
Cancer Res. 2008 May 1;68(9):3421-8
18451170
Oncotarget. 2016 Jun 7;7(23):33512-28
27172899
Nature. 2010 Jan 7;463(7277):103-7
20023629
N Engl J Med. 2005 Mar 10;352(10):997-1003
15758010